Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-08
2005-02-08
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254110, C544S377000, C544S400000
Reexamination Certificate
active
06852723
ABSTRACT:
Novel compounds of the general formula:and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4558129 (1985-12-01), Kluge et al.
patent: 4567264 (1986-01-01), Kluge et al.
patent: 4766125 (1988-08-01), Van Daele
patent: 5472707 (1995-12-01), Samuels et al.
patent: 5506229 (1996-04-01), Dow
patent: 5670171 (1997-09-01), Santus et al.
patent: 5906988 (1999-05-01), Dow
patent: 2054544 (1992-05-01), None
patent: 0 068 544 (1983-01-01), None
patent: 0 143 016 (1985-05-01), None
patent: 0 407 780 (1991-01-01), None
patent: 0 483 932 (1992-06-01), None
patent: 03 141258 (1991-06-01), None
Pepine et al., “A Controlled Trial with a Novel Anti-Ischemic Agent, Ranolazine, in Chronic Stable Angina Pectoris That is Responsive to Coventional Antianginal Agents”,American Journal of Cardiology, vol. 84, pp. 46-50 (1999).
Blackburn Brent K.
Elzein Elfatih
Ibrahim Prabha N.
Marquart Tim
Palle Venkata P.
Bernhardt Emily
CV Therapeutics Inc.
CV Therapeutics, Inc.
LandOfFree
Aralkyl substituted piperazine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aralkyl substituted piperazine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aralkyl substituted piperazine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3453283